Europe’s Medical Device Regulation (MDR, Regulation 2017/745) replaced the Medical Devices Directive (MDD, 93/42/EEC) and introduced substantially higher requirements for clinical evidence, post-market surveillance, and Notified Body scrutiny. For medical robots — which often combine complex software, mechanical systems, and high-risk intended uses — the transition from MDD to MDR represents a meaningful increase in regulatory burden.
The Core Shift: Directive to Regulation
The MDD was a Directive, meaning EU member states transposed it into national law with some variation in implementation. The MDR is a Regulation — it applies directly and uniformly across all EU member states without national transposition. This eliminates the forum shopping that some manufacturers used under MDD to certify through Notified Bodies in jurisdictions with lighter-touch enforcement.
The MDR entered into force in May 2017 and became fully applicable in May 2021 after two COVID-related extensions. A further transition period for legacy MDD-certified devices was extended multiple times by the EU legislature, with the final dates depending on device class.
Classification Changes Affecting Robots
The MDR revised classification rules in ways that affected several medical robot categories:
Software reclassification. Under MDD Rule 10, most software was Class I or IIa. MDR Rule 11 reclassified software that provides information used to make decisions with diagnosis or therapy implications to Class IIa or higher — in some cases Class III. Control software integral to a surgical robot that guides cutting depth or instrument trajectory is affected by this rule. Manufacturers who had separate software certificates under MDD may need consolidated or elevated Class IIb/III assessments under MDR.
Active therapeutic devices. MDR Rule 9 (active devices intended to administer energy to or exchange energy with the body) was clarified in ways that affect energy-delivery subsystems in surgical robots — electrosurgical tools, laser components, and ultrasonic systems integrated into robotic platforms.
Combination products. Robotic platforms that include medicinal substances or human tissue components face additional requirements under MDR Annex I that did not exist under MDD in the same form.
Clinical Evidence Requirements
MDD permitted manufacturers to support certification with literature reviews and equivalence arguments — citing clinical data from predicate devices rather than generating new clinical evidence. MDR substantially tightens this:
Stricter equivalence criteria. Under MDR Annex XIV, claiming equivalence to another device requires demonstrating technical, biological, and clinical equivalence. For Class III devices and implantables, equivalence claims require a contract with the predicate device manufacturer allowing access to technical documentation — effectively preventing unilateral literature-based equivalence arguments against a competitor’s device.
Post-Market Clinical Follow-Up (PMCF). MDR requires an ongoing PMCF plan, not just a one-time pre-market study. For surgical robots, PMCF typically means registries, systematic follow-up studies, or analysis of real-world use data, with periodic reporting through Post-Market Surveillance Reports (PMSR) or Periodic Safety Update Reports (PSUR) depending on device class.
Clinical Evaluation Reports (CER). CERs must be kept current — MDR does not allow a static CER written at time of certification to serve indefinitely. For high-risk devices including Class IIb and Class III robots, annual or biennial updates are expected.
Notified Body Changes
Under MDD, dozens of Notified Bodies were authorized in Europe with varying levels of technical depth. MDR introduced new designation criteria under Article 36 and Annex VII that required Notified Bodies to demonstrate product-specific expertise and minimum staffing in relevant technical domains.
The result was a significant contraction: many Notified Bodies did not seek or receive MDR designation, and those that did took several years to build capacity. This created a bottleneck that contributed to certification delays across the industry in 2021–2023.
For surgical robots specifically, Notified Bodies must now conduct unannounced audits and review the complete technical file — not a sample. For Class III devices including high-risk robotic surgical systems, the Notified Body must also consult a panel of clinical experts and coordinate with a competent authority on clinical aspects.
Unique Data Requirements (UDI)
MDR introduced mandatory Unique Device Identification (UDI) requirements with phased timelines by device class. Class III devices (including high-risk surgical robots) were required to register UDIs in EUDAMED first. The UDI system enables traceability from manufacturer through distributor to specific patients, and supports post-market signal detection.
Surgical robot manufacturers selling in Europe must register each device model in EUDAMED and keep the device record current. EUDAMED’s public-facing database also increases transparency — buyers and regulators can query certification status directly.
What This Means for Chinese Robot Manufacturers
Chinese manufacturers seeking European market access face the same MDR requirements as any other manufacturer. The practical implications:
Notified Body availability. Access to an MDR-designated Notified Body with surgical robotics expertise has been constrained. Companies entering the European market now should verify their chosen Notified Body is designated under MDR for the relevant device categories before investing in a full technical file.
Clinical data strategy. Chinese clinical trial data conducted under NMPA requirements may not directly satisfy MDR clinical evaluation standards. Manufacturers typically need to conduct a gap analysis and may need EU-based PMCF studies or supplemental data collection.
Representative requirements. Non-EU manufacturers must appoint an EU Authorised Representative (EU AR), who carries legal responsibility for the device’s compliance. Choosing the EU AR involves legal and liability considerations beyond the technical file.
Frequently Asked Questions
When did MDD certificates expire?
Under the extended transition timeline (EU Regulation 2023/607), MDD certificate validity depended on risk class: Class III devices and Class IIb implantable devices could remain valid until December 31, 2027, while non-implantable Class IIb devices and Class IIa devices had a December 31, 2026 deadline. Class I devices had an earlier deadline still. Validity also required that the certificate was issued before May 26, 2021, the device had not undergone significant changes, and the manufacturer remained under active surveillance. Manufacturers should verify current transition dates with their Notified Body, as the EU legislature has amended these timelines multiple times.
Is MDR harder than NMPA Class III?
They are different rather than strictly harder or easier. MDR places heavier emphasis on continuous post-market clinical follow-up and current clinical evidence. NMPA places heavier emphasis on a prospective domestic clinical trial before initial registration. A device may satisfy one without automatically satisfying the other.
Do surgical robots need a Notified Body for MDR, or can they self-certify?
Class III surgical robots require Notified Body involvement — there is no self-certification pathway for Class III devices under MDR. Class I devices (with no measuring function, no sterile presentation, and no reuse) can self-certify, but most robotic surgical systems are Class IIb or Class III.
What is EUDAMED and who can access it?
EUDAMED is the European Database on Medical Devices. Some sections are publicly accessible — device registration, UDI lookup, certificate status — while others (such as vigilance and market surveillance modules) are accessible only to regulators and manufacturers. Buyers and procurement teams can use the public UDI database to verify a device’s certification status.
Does MDR apply to devices sold to hospitals in the UK after Brexit?
No. Following Brexit, the UK Medical Device Regulations and the UKCA marking system govern devices sold in Great Britain (England, Scotland, Wales). Northern Ireland has a more complex arrangement under the Windsor Framework. CE marking under MDR still applies to devices sold in EU member states.